Protocol Ledger

NCT04442022 · Phase II/III · ACTIVE NOT RECRUITING

A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Interventional Phase II/III clinical trial protocol NCT04442022 sponsored by Karyopharm Therapeutics in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-09-03 Enrollment: 501 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT04442022
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)501 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04442022
Protocol FieldVerified Registry Value
NCT IdentifierNCT04442022
Consolidated Lead SponsorKaryopharm Therapeutics
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II/III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment501 participants (ESTIMATED)
Registered Start Date2020-09-03
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04442022
Hospital Research SiteLocationSite Profile
Texas Oncology (Tyler)Tyler, TXOpen Hospital Dossier ->
Jiangsu Province HospitalNanjing, ChinaOpen Hospital Dossier ->
The First Affiliated Hospital Of Soochow UniversitySuzhou, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI